Resolving Our Uncertainty about Oxygen Therapy

Pediatrics

Volumn 112, Issue 6 I, 2003, Pages 1415-1419

  Cole, Cynthia H ^a,b   Wright, Kenneth W ^c   Tarnow Mordi, William ^d   Phelps, Dale L ^e  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIAL OXYGEN TENSION; GESTATIONAL AGE; HUMAN; NEWBORN CARE; NEWBORN MORTALITY; NOTE; OUTCOMES RESEARCH; OXYGEN THERAPY; PREMATURITY; PRIORITY JOURNAL; PULSE OXIMETRY; RETROLENTAL FIBROPLASIA; RISK FACTOR; SAFETY; TISSUE OXYGENATION; TRANSCUTANEOUS OXYGEN MONITORING; TREATMENT INDICATION; TREATMENT PLANNING;

HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE, NEONATAL; LUNG DISEASES; OXIMETRY; OXYGEN; OXYGEN CONSUMPTION; RANDOMIZED CONTROLLED TRIALS; RETINOPATHY OF PREMATURITY;

EID: 0346850818     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.112.6.1415     Document Type: Note

References (43)

1. Tin W. Oxygen therapy: 50 years of uncertainty. Pediatrics. 2002;110: 615-616
2. Tin W, Wariyar U. Giving small babies oxygen: 50 years of uncertainty. Semin Neonatol. 2002;7:361-367
3. Lucey JF, Dangman B. A reexamination of the role of oxygen in retrolental fibroplasia. Pediatrics. 1984;73:82-96
4. Chan-Ling T GB, Stone J. Supplemental oxygen therapy: basis for non-invasive treatment of retinopathy of prematurity. Invest Ophthalmol. 1215;36:1215-1230
5. Phelps DL. Reduced severity of oxygen-induced retinopathy in kittens recovered in 28% oxygen. Pediatr Res. 1988;24:106-109
6. The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes. Pediatrics. 2000;105: 295-310
7. Askie L, Henderson-Smart D, Irwig L, Judy Simpson. Oxygensaturation targets and outcomes in extremely preterm infants. N Engl J Med. 2003;349:959-967
8. Patz A, Hoeck LE, De LA, Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. 1. Nursery observations. Am J Ophthalmol. 1952;36:1248-1253
9. Patz A. Oxygen studies in retrolental fibroplasia. IV. Clinical and experimental observations. Am J Ophthalmol. 1954;38:291-308
10. Lanman JT, Guy LP, Dancis J. Retrolental fibroplasia and oxygen therapy. JAMA. 1954;155:223-226
11. Kinsey VE. Retrolental fibroplasia: cooperative study of retrolental fibroplasia and the use of oxygen. Arch Ophthalmol. 1956;56:481-543
12. Weintraub DH, Tabankin A. Relationship of retrolental fibroplasia to oxygen concentration. J Pediatr. 1956;49:75-79
13. 2 levels and retrolental fibroplasia: a report of the cooperative study. Pediatrics. 1977;60:655-668
14. Engle MA, Baker DH, Baras I, et al. Oxygen administration and retrolental fibroplasia. Am J Dis Child. 1955;89:399-413
15. Engle MA, Levine SZ. Response of small premature infants to restriction of supplementary oxygen. Am J Dis Child, 1955;89:316-324
16. Tin W, Milligan DW, Pennefather P, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed. 2001;84:F106-F110
17. Vijayakumar E, Ward GJ, Bullock CE, Patterson ML. Pulse oximetry in infants of <1500 gm birth weight on supplemental oxygen: a national survey. J Perinatol. 1997;17:341-345
18. 2 levels and clinical outcome in ELBW infants on supplemental oxygen [abstract]. Pediatr Res. 2002;51:350A
19. Anderson CG, Benitz WE, Madan A. Retinopathy of prematurity (ROP) and pulse oximetry: a national survey of recent practices [abstract]. Pediatr Res. 2002;51:367A
20. Ellsbury DL, Acarregui MJ, McGuinness GA, Klein JM. Variability in the use of supplemental oxygen for bronchopulmonary dysplasia. J Pediatr. 2002;140:247-249
21. Saugstad OD. Is oxygen more toxic than currently believed? Pediatrics. 2001;108:1203-1205
22. Oxygen and retrolental fibroplasia: the questions persist. Pediatrics. 1977;60:753-754
23. Duc G, Sinclair JC. Oxygen administration. In: Sinclair JD, Bracken MB, eds. Effective Care of the Newborn Infant. Oxford, United Kingdom: Oxford University Press; 1992:178-198
24. Askie LM, Henderson-Smart DJ. Restricted versus liberal oxygen exposure for preventing morbidity and mortality in preterm or low birth weight infants. Cochrane Database Syst Rev. 2000;(2): CD001077
25. Avery ME, Oppenheimer E. Recent increase in mortality in hyaline membrane disease. J Pediatr. 1960;57:553-559
26. McDonald A. Neurological and ophthalmic disorders in children of very low birth weight. Br Med J. 1962;1:895-900
27. Cross KW. Cost of preventing retrolental fibroplasia? Lancet. 1973; 2(7835):954-956
28. Flynn JT, Bancalari E, Bawol R, et al. Retinopathy of prematurity: a randomized, prospective trial of transcutaneous oxygen monitoring. Ophthalmology. 1987;94:630-638
29. Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med. 1992;326:1050-1054
30. Chow LC, Wright KW, Sola S. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics. 2003;111:339-345
31. 2) levels [abstract]. Biol Neonate. 2003;84:267
32. Peto R, Baigent C. Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ. 1998;317:1170-1171
33. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2(8607):349-360
34. Elwood P. Cochrane and the benefits of aspirin. In: Maynard A, Chalmers I, eds. Non-random reflections on health services research: on the 25th anniversary of Archie Cochrane's effectiveness and efficiency. London, United Kingdom: BMJ Publishing Group; 1997:107-121
35. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA. 1995;273:413-418
36. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev. 2003;3
37. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34:585-612
38. The OSIRIS Collaborative Group (Open Study of Infants at High Risk of or With Respiratory Insufficiency-the Role of Surfactant). Early versus delayed neonatal administration of a synthetic surfactant - the judgement of OSIRIS. Lancet. 1992;340:1363-1369
39. Schmidt B, Davis P, Moddemann D, et al; Trial of Indomethacin Prophylaxis in Preterms Investigators. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001; 344:1966-1972
40. Kenyon SL, Taylor DJ, Tarnow-Mordi W; ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. Lancet. 2001;357: 979-988
41. Tucker J, Parry G, Nicholson P, McCabe C, Tamow-Mordi W; UK Neonatal Staffing Study Group. Patient volume, staffing, and workload in relation to risk-adjusted outcomes in a random stratified sample of UK neonatal intensive care units: a prospective evaluation. Lancet. 2002; 359:99-107
42. Horbar JD, Badger GJ, Carpenter JH, et al. Trends in mortality and morbidity for very low birth weight infants, 1991-1999. Pediatrics. 2002; 110:143-151
43. CLASP Collaborative Group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. Br J Obstet Gynaecol. 1995;102:861-868